CHICAGO — Roche had previously announced the failure of its closely tracked anti-TIGIT immunotherapy in a study involving patients with small cell lung cancer. But new details revealed for the first time Sunday showed the drug, called tiragolumab, had no activity at all — adding to the questions about its future.
In the study called SKYSCRAPER-02, tiragolumab combined with a two-drug standard of care performed worse than the control arm. The tiragolumab regimen elevated the risk of tumors progressing by 11% compared to standard therapy alone, which consisted of Tecentriq, Roche’s currently approved PD-L1 checkpoint inhibitor, and chemotherapy.
At the median, patients with small cell lung cancer treated with tiragolumab, Tecentriq, and chemotherapy went 5.4 months without their tumors progressing, compared to 5.6 months for the patients administered Tecentriq and chemotherapy alone. Small cell lung cancer is less common but more aggressive and difficult to treat than other types of lung cancer.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
